Cytokinetics Inc (NAS:CYTK)
$ 48.98 -10.25 (-17.31%) Market Cap: 5.14 Bil Enterprise Value: 6.35 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Q1 2020 Cytokinetics Inc Earnings Call Transcript

May 06, 2020 / 08:30PM GMT
Release Date Price: $16.63 (+1.28%)
Operator

Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' First Quarter 2020 Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)

I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President and -- of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser
Cytokinetics, Incorporated - Senior VP of Corporate Communications & IR

Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and the impacts of COVID-19 on certain clinical trials. Then Fady Malik, our EVP of Research and Development, will provide updates on key developments for omecamtiv mecarbil, our cardiac myosin activator, and AMG 594, our cardiac troponin activator, both under our collaboration with Amgen. Next, Stuart Kupfer, our SVP and Chief Medical Officer, will update on recent progress with CK-274, our wholly owned cardiac myosin inhibitor now in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot